The company’s transformer model interprets up to one billion DNA fragments in each blood sample, capturing molecular context at a scale hundreds of times greater than leading LLMs and demonstrating strong clinical validation. With $6.7 million seed led by Felicis Ventures and Illumina Ventures, Hepta advances liquid biopsy platforms beyond oncology.
Breakthrough high-protein chickpea variety answers rising demand for sustainable and minimally processed protein ingredients.
Eurostar grant supports application of BioLizard’s AI expertise to Broken String’s INDUCE-seq® platform; Resulting technology, called SafeGuide, will enable faster, more cost-effective development of gene edited therapies like CRISPR.
Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
